LLY Oct 2024 1060.000 call
| Previous Close | 0.1800 |
| Open | 0.1000 |
| Bid | 0.0200 |
| Ask | 0.1000 |
| Strike | 1,060.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.1000 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 469 |
Yahoo FinanceWhat end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand. What does that mean for the marketplace?
- Yahoo Finance Video
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
Eli Lilly's (LLY) GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors, like Novo Nordisk (NVO). For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
ZacksEli Lilly (LLY) Rises But Trails Market: What Investors Should Know
Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.
